FDA granted Fast Track and Orphan Drug designation for Tivic Health Systems, Inc. following company announcements regarding results from Fremont on August 7, 2025.
2 reports, 2 independent
Updated Aug 7
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted Fast Track and Orphan Drug designation for Tivic Health Systems, Inc. following company announcements regarding results from Fremont on August 7, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Tivic Health Systems, based in Fremont, announced that the FDA approved its VNS treatments on June 25, 2025.Sub-event
- FDA granted Fast Track designation for Tivic Health Systems' TLR5 agonist Entolimod, and Lisa Wolf assumed CFO role.Sub-event
FDA granted Fast Track and Orphan Drug designation for Tivic Health Systems, Inc. based on Fremont results.1 source
Keep exploring
The entities involved
Related events
- FDA granted Orphan Drug Designation to BRC's drug.
- FDA granted Fast Track designation to SAB-142 on November 1, 2026.
- The FDA granted Fast Track Designation for RAD101, following company announcements made on July 29, 2025, from Sydney.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA failed to update warning labels despite confirmed risks associated with a product.
Coverage
Newest first; wire copies grouped- Business WireTivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast FREMONT, Calif., August 07, 2025--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIV
- MedTech DiveCMS proposes covering renal denervation for hypertension This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter.